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Background: Pulmonary renal syndrome (PRS), denoting the presence of diffuse alveolar hemorrhage and
glomerulonephritis as manifestations of systemic autoimmune disease, is very rare in childhood. The coexistence of
circulating anti-neutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane (GBM) disease in
children affected by this syndrome is exceptional, with unfavorable outcome in five out of seven patients reported
to date. We describe a child with PRS associated with both circulating anti-myeloperoxidase (anti-MPO) ANCA and
anti-GBM disease on renal biopsy who was successfully treated with immunosuppressive therapy.
Case presentation: A 10-year old girl presented with fever, fatigue, malaise, and pallor followed by hemoptysis and
severe anemia. Diffuse alveolar hemorrhage was revealed on fiberoptic bronchoscopy. Renal findings consisted of
microscopic hematuria, moderate proteinuria, and anti-GBM disease on renal biopsy. ANCA with anti-MPO
specificity were present whereas anti-GBM antibodies were on borderline for positivity. Methyl-prednisolone pulses
followed by prednisone led to cessation of hemoptysis, marked improvement of lung fuction, and normal finding
on chest x-ray within 10 days. An immunosuppressive regimen was then given consisting of prednisone daily for 4
weeks with subsequent taper on alternate day, i.v. cyclophosphamide pulses monthly for 6 doses, followed by
mycophenolate mofetil that resulted in normal lung function tests, hemoglobin concentration, and anti-MPO level
within four subsequent weeks. During 10-months of follow-up she remained well, her blood pressure and renal
function tests were normal, and proteinuria and hematuria gradually resolved.
Conclusion: We report a child with an exceptionally rare coexistence of circulating ANCA and anti-GBM disease
manifesting as PRS in whom renal disease was not the prominent part of clinical presentation, contrary to other
reported pediatric patients. A review of literature on disease with double positive antibodies is also presented.
Evaluation of a patient with PRS should include testing for presence of different antibodies. An early diagnosis and
rapid institution of aggressive immunosuppressive therapy can induce remission and preserve renal function. Renal
prognosis depends on the extent of kidney injury at diagnosis and appropriate treatment.
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The term pulmonary renal syndrome (PRS) describes
the presence of diffuse alveolar hemorrhage (DAH) and
glomerulonephritis as manifestations of multisystemic
autoimmune disease often resulting in severe, life-
threatening condition requiring urgent, aggressive treat-
ment [1,2]. It is very rare in children. The most common
reported causes are systemic lupus erythematosus, anti-
neutrophil cytoplasmic antibody (ANCA)-associated vas-
culitis (AAV), anti-glomerular basement membrane
(GBM) disease, and Henoch-Schonlein purpura [3]. Cir-
culating antibodies against GBM and ANCAs are both
associated with crescentic glomerulonephritis (CGN)
and DAH [4,5]. Their coexistence (double or dual posi-
tivity) was found in a subset of adult patients at disease
presentation indicating a pathogenic link [6-13]. In chil-
dren, this coexistence is extremely rare with only seven
patients reported to date, five of them had an unfavor-
able outcome [6,14-18].
We present an exceptional case of a 10-year old girl
with DAH and focal necrotizing CGN associated with
circulating anti-myeloperoxidase (anti-MPO) ANCA and
concomitant anti-GBM disease on renal biopsy who was
successfully treated with immunosuppressive therapy.
Contrary to other reported pediatric patients, renal dis-
ease was not the prominent part of clinical presentation.
Pathogenesis, clinical course, treatment and outcome of
disease with double positivity are discussed based on a
review of reports in adults and children.
Case presentation
Previously healthy 10-year old girl presented with inter-
mittent fever up to 38,5°C, fatigue, malaise, occasional
headaches, legs pain and pallor. The symptoms did not
prompt her or her parents to seek medical help. Two
weeks later she began to cough, when laboratory investi-
gation showed severe anemia with hemoglobin of 44 g/l
and she was admitted to the local hospital. Chest X-ray,
echocardiography and ultrasound examination of abdo-
men were normal. After receiving transfusion of packed
red blood cells (RBC) she was referred to regionalFigure 1 Chest X-ray (a) and CT scan (b) showing bilateral lung infiltrhospital. During 2 weeks stay she received packed RBC
transfusion on two occasions but moderate anemia
(hemoglobin up to 94 g/l) persisted. There were no signs
of hemolysis and bone marrow examination was normal.
Urinalysis showed microscopic hematuria and persistent
mild to moderate proteinuria (+ to ++ on dipstick) with
normal renal function tests (urea 4.5 mmol/l, creatinine
47 μmol/l). A week after admission she started with dry
cough again and began to expectorate blood-tinged spu-
tum. On physical examination, inspiratory crackles over
both lower lung fields were noted. Her anemia has wors-
ened (hemoglobin 72 g/l), chest X-ray showed bilateral
patchy pulmonary infiltrates (Figure 1a) and active pul-
monary hemorrhage was suspected. This was supported by
finding of patchy areas of ground-glass opacities on chest
computed tomography scan (Figure 1b) suggesting diffuse
alveolar hemorrhage. Therapy with prednisone, 20 mg/day
was started and she was transferred to our hospital.
On admission, she was pale with body height (149 cm)
and body weight (40 kg) at 90. Percentile. Inspiratory
crackles were present bilaterally over her lower lung
fields, but the rest of physical examination was unre-
markable. Blood pressure (BP) was 90/60 mmHg. Chest
X-ray showed bilateral patchy pulmonary infiltrates in
the middle and lower lung fields. Flexible fiber optic
bronchoscopy revealed the presence of bilateral alveolar
bleeding with progressively more hemorrhagic samples
obtained by consecutive aliquots during bronchoalveolar
lavage. The cytological analysis of these specimens
showed presence of numerous hemosiderin-laden mac-
rophages. Pulmonary function testing showed restrictive
lung disease pattern (vital capacity – VC 71% and total
lung capacity – TLC 74% predicted). Blood counts were:
Hb 104 g/l, RBC 3.8×1012/l, WBC 11.1×109/l, Plt
411×109/l, Rtc 3.12%. Serum urea and creatinin levels
were normal. Urinalysis showed microscopic hematuria
(8–10 RBC/hpf ) and mild proteinuria (474 mg/24 h).
Presence of pulmonary and renal manifestations sug-
gested further serological testing. Antinuclear antibodies
(ANA) and anti-double stranded DNA (anti-dsDNA)
antibodies were negative, and C3 and C4 components ofates as a result of diffuse alveolar hemorrhage.
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(IIF) revealed perinuclear ANCA (p-ANCA) at a titer of
1:80 with antimyeloperoxidase (anti-MPO) ANCA specifity
by ELISA (52.7 U/ml, normal <5 U/ml); IIF for cytoplasmic
ANCA (c-ANCA), and ELISA for antiproteinase 3 (anti-
PR3)-ANCA were negative, but anti-glomerular basement
membrane (anti-GBM) antibodies titer (ELISA) was on
borderline for positivity (19.7 RU/ml, normal <20 RU/ml).
She was immediately given i.v. methylprednisolone (MP)
pulses (600 mg/m2/day) for 3 days, followed by prednisol-
one, 40mg/day, which resulted in cessation of hemoptysis,
marked improvement of lung function (VC 90%, TLC 91%)
and normal finding on chest X-ray within 10 days.
However, moderate anemia persisted together with
moderate proteinuria (638 mg/24 h) and microscopic
hematuria. Percutaneous renal biopsy was perfomed and
tissue samples were analyzed by light microscopy (LM)
and immunofluorescence (IF). LM showed cellular cres-
cents in 4 out of 25 glomeruli and fibrinoid necrosis in 1
of 25 glomeruli (Figure 2a), with lymphomonocytic intersti-
tial infiltration around glomeruli with crescents and perivas-
cular infiltration of small arterioles; IF showed diffuse global
linear staining of the GBM for IgG (Figure 2b) accompanied
by segmental linear to granular staining for C3, suggesting
anti-GBM disease [5,19,20]. Diagnosis of pulmonary-renal
syndrome caused by anti-GBM disease and coexistent AAV
was made. The treatment was then changed to a regimen
consisting of prednisone (60 mg/day) for 4 weeks with sub-
sequent taper to 30 mg on alternate day; i.v. cyclophospha-
mide (CY) pulses (0.5–0.75 g/m2) were given monthly for
total of 6 doses, followed by mycophenolate mofetil
(MMF; 600 mg/m2 b.d.) [19,21]. Four weeks after starting
this treatment her hemoglobin level (132 g/L) and pul-
monary function tests (FVC 100%, FEV1 97%) were nor-
mal, p-ANCA/anti-MPO ANCA returned to normal and
anti-GBM antibodies were undetectable. During the
10-month follow-up she remained well, her BP and
renal function test remained normal. Proteinuria
remained unchanged during the first 8 months but
gradually resolved thereafter, whereas two episodes of
macroscopic hematuria on two occasions were occured,Figure 2 Light microscopy and immunofluorescent findings on renal bio
periglomerular limpho-monocytic infiltration (PAS, ×400); (b) Immunofluorescenduring unspecific febrile illnesses. At the latest follow-up
visit, 10 months after starting treatment, her body weight
was 44 kg, BP was 96/58 mmHg, with normal findings on
physical examination and normal pulmonary function
tests. Her complete blood count was normal, whereas 4–6
RBC/hpf in urine sediment were only present. Blood
and urine laboratory values were as follows: urea 4.5
mmol/l, creatinine 59 μmol/l, p-ANCA negative; anti-
MPO ANCA 3.5 U/ml; anti-GBM antibodies undetect-
able; proteinuria 116 mg/24 h. Her drug therapy
consisted of prednisone 15 mg on alternate day, and
MMF dose was reduced to 750 mg/day.
Discussion
The combination of DAH and acute or rapidly progressive
(crescentic) glomerulonephritis, known as Goodpasture
syndrome, is used interchangeably with PRS since several
different pathogenic mechanisms underlie this clinical en-
tity [16,22]. PRS most commonly results from AAV or
anti-GBM disease but is also described in lupus, Henoch-
Schönlein purpura, rheumathoid arthritis and other con-
nective tissue diseases [2].
In the anti-GBM disease the deposition of autoantibodies
in the glomerular and alveolar basement membranes induces
glomerulonephritis and pulmonary hemorrhage. The target
antigen for the autoantibodies is the non-collagenous-1
(α3NC1) domain of type IV collagen in the GBM, with
changes in structure of the α345 hexamer leading to con-
formation change that elicits this autoimmune response [23].
In renal biopsies, linear positivity for IgG along the GBM in-
dicates the direct pathogenetic relevance of this antibody [5].
ANCA-associated systemic vasculitides are character-
ized by necrotizing inflammation of the small vessels in
conjunction with ANCA directed to myeloperoxidase or
proteinase-3 [24]. It is shown that ANCA IgG can activate
neutrophils and monocytes through Fc receptor and Fab2
binding leading to their adhesion to endothelial cells and
release of cytotoxic factors which results in inflammatory
injury of endothelial cells and vessel walls [5,25].
Several studies in adults reported patients with concur-
rence of ANCA and anti-GBM antibodies. Approximatelypsy. (a) Fibrinoid necrosis of GBM, cellular crescentic formation, and slight
ce: fine linear pattern along GBM stained with anti IgG antibody (×200).
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GBM antibodies [6,10,26], and 21–38% of anti-GBM
antibody-positive patients also had positive ANCAs
[6-10,26,27], with specificity to MPO in at least two thirds
of them [6-11,26,27]. The relatively high incidence of such
dual positivity indicates a pathogenic link, which still has
to be unraveled. Several pathogenetic hypothesis have
been proposed to explain this coexistence, the most at-
tractive one suggests an ANCA development as the initial
event, with ANCA-associated mechanisms leading to the
exposure of the otherwise hidden α-3(IV)NC1 antigen and
triggering anti-GBM antibody production [11,23,28]. This
hypothesis is supported by the reports on sequential posi-
tivity of ANCA followed by anti-GBM antibodies [26,29],
by the strong association between elevated ANCA titers
and anti-GBM disease [14,19], and by the recent findings
that anti-PR3 and/or anti-MPO antibodies were always
detected long before anti-GBM antibodies in anti-GBM
disease patients [30]. However, the opposite sequence in
double positive patients is also described [31-33].
There are reports that dual positivity in anti-GBM dis-
ease may be related to a different clinical course, at least
in some patients. Older studies showed more favorable
course with significant renal recovery after initiating dia-
lysis [6,7,34], but more recent reports concluded that
renal prognosis is comparable to anti-GBM disease and
is worse compared to patients with anti-MPO antibodies
[10,11]. It has also been noted that incidence of pulmon-
ary hemorrhage is lower in adult double-positive pa-
tients than in patients with ANCA-negative anti-GBM
disease [6], and that dual positivity is associated with
lower anti-GBM titers [6,7,27]. While pure anti-GBM dis-
ease is generally considered monophasic, non-relapsing
illness [5,10,12,19], AAV has a recurrence rate of 30–60%,
demanding maintenance therapy after induction of remis-
sion [35]. Dual positive patients have higher relapse rate
then those with anti-GBM antibodies alone [6,9]. This
suggests that an early indicator of disease relapse is
needed in monitoring disease activity in double-positive
patients, such as anti-hLAMP2 antibody [36,37].
Optimal therapy for double-positive patients has not been
identified yet. Because of the risk of serious disease with
multiple organ involvement and possible relapsing course,
the addition of plasmapheresis to an immunosuppressive
regimen given for AAV with continuing immunosuppres-
sion with azathioprine after 3–6 months of cyclophospha-
mide is recommended for these patients [38,39].
In most adult double positive patients the reported out-
come was poor both in terms of the recovery of renal func-
tion and mortality [2,6,10,11]. The best predictor for renal
survival was renal function at diagnosis: recovery of renal
function in dialysis dependent patients is exceptionally rare
[7,10,40] as well as in those with serum creatinine exceeding
500 μmol/l despite undergoing treatment [6,7,10-12,34]. Inpatients who were not dialysis dependent at diagnosis, renal
function depended on histological severity of disease [34].
Patients with pulmonary hemorrhage had significantly
higher mortality compared to those without pulmonary
hemorrhage [10]. The recurrence of disease activity with ele-
vation of MPO-ANCA can occur many months after clinical
remission, affecting either both lungs and kidneys or only
one of these organs [6,12,13,31,32,41]. Most relapses
responded well to methylprednisolone and/or cyclophos-
phamide therapy [12,36].
The initial symptoms in our patient were similar to
those often preceding AAV or may represent a possible in-
fectious trigger either for one or both diseases [19,20].
This was followed by pulmonary hemorrhage with accom-
panying severe anemia. However, renal disease was rela-
tively mild consisting of microscopic hematuria and mild
to moderate proteinuria. Renal biopsy showed focal CGN
with only occasional extraglomerular vasculitic changes,
but without chronic glomerular or tubulointerstitial le-
sions. Fibrinoid necrosis with extraglomerular vasculitic
changes, associated with positive pANCA/anti-MPO anti-
bodies indicated pauci-immune ANCA disease whereas
intense linear IgG staining of the GBM pointed out to an
anti–GBM disease [5,19,20], irrespective of normal
(though high-normal) serum anti-GBM antibodies level
[42]. Only active lesions were present implying the recent
onset of disease. Good clinical response of pulmonary dis-
ease to corticosteroid treatment and clinically and patho-
logically mild to moderate renal disease led us to withhold
plasmapheresis from recommended treatment regimen
[19,21]. The subsequent course was very favorable in view
of pulmonary symptoms, global renal function, rapid dis-
appearance of anti-GBM antibodies and normalization of
anti-MPO antibodies. However, the substantially un-
changed proteinuria and bouts of macroscopic hematuria,
that could reflect continuing vasculitic disease activity
despite normal anti-MPO antibody titer [43], led us to
introduce mycophenolate mofetil after stopping cyclo-
phosphamide therapy [19], as an adjunct to the above
regimen. One must assume that both the stability of pul-
monary remission and lately achieved complete remission
were related to an early intensive corticosteroid and CY
therapy, followed by MMF.
The coexistance of anti-GBM antibodies and ANCAs
is extremely rare in children. Searching PubMed, we
were able to retrieve only seven pediatric cases reported
to date, either within case series [6,18] or as single case
reports [14-17]. Their main features together with those
in our patient are presented in Table 1. Six out of eight
patients were females, aged between 4–17 years. PRS
was presenting feature in all except in the youngest pa-
tient [17]. Preceding constitutional symptoms or differ-
ent organ involvement were present in five of them.
Crescentic glomerulonephritis with positive IgG linear
Table 1 Main features of the reported double-positive pediatric patients
Patient
[ref]
Age (yr, sex) Initial
symptoms








1 [14] 17, f URTI ~ 6.0 12.5 - + p/MPO 90 supportive - Death at
presentation
2 [15] 12, f - 7.4 0.5 0.3 + p/MPO 13 MP, PE, CY few weeks Normal GFR
3 [16] 12, m fever,rash,
arthritis
10.6 7.4 2.1 + p/MPO >60 PE, MP, CY Pdn,
MMF
18 mos GFR 58.5 ml/min
4 [17] 4, f epistaxis n.a. 2.7 0.8 + p/MPO 62 PE, MP, Pdn, CY 9 mos Normal GFR
5 [18] 8, f sore throat 2.8 7.7 - - p/MPO 83 supportive - Death at
presentation
6 [6] 13, m rash, sinusitis n.a. D D + c/PR3 + PE, Pdn, CY n.a. ESRD
7 [6] 17, f n.a. D D + p/MPO 20 PE, CY, Pdn, Aza n.a. ESRD
8 [this
report]
10, f fever, malaise,
legs pain
4.4 0.53 0.66 ± p/MPO 16 MP, CY, Pdn,
MMF
10 mos Normal GFR
URTI, upper respiratory tract infection; F/U, follow-up; Abs, antibodies; p, perinuclear; MPO, myeloperoxidase; PR3, proteinase-3; MP, methyl-prednisolone; PE, plasma exchange; CY, cyclophosphamide; GFR, glomerular
filtration rate; Pdn, prednisone; MMF, mycophenolate mofetil; Aza, azathioprine; ESRD, end-stage renal disease; D, dialysis; S-Cr, serum creatinine concentration; GBM, glomerular basement membrane;
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with percentage of crescents ranging from 13% to 90%
in kidney biopsy samples. In one patient, an 8-year old
girl [18], circulating anti-GBM antibodies were not
detected whereas they were at the upper limit of normal
in our patient, despite prominent linear IgG staining in
the GBM in both of them. It has been estimated that
2–3% of patients with anti-GBM disease may have cir-
culating antibody levels that are undetectable by stand-
ard assays, but can be detected by a more sensitive
method [42]. In these cases, diagnosis of anti-GBM
disease may be based on intense linear staining of the
GBM after exclusion of other conditions, also present-
ing with linear staining, but extremely rare in children
[5,42]. Only one patient had c-ANCA with anti-PR-3
specifity, whereas p-ANCA/anti-MPO antibodies were
found in other seven patients. Although MPO specifity
is the predominant pattern found in dual positivity,
this phenomenon can be seen either with MPO or PR3
[6,32]. All survived patients were treated by combin-
ation of immunosuppressive drugs and all except our
patient received plasmapheresis.
In both AAV and anti-GBM disease the addition of
plasmapheresis to initial immunosuppressive therapy is indi-
cated in patients with severe renal dysfunction or with DAH
[19,20,38,39]. The recommendation for plasmapheresis in
double positive patients is based on the rationale for the
treatment of anti-GBM disease [38,39]. The observation of
worse outcome in patients with double positivity compared
to those with either AAV or anti-GBM disease alone [11]
may add further support to this strategy. However, it is un-
known whether patients with milder alveolar hemorrhage
require plasmapheresis [38]. According to these criteria,
plasmapheresis was indicated in our patient. However, quick
favorable response to intensive immunomodulating therapy
as well as the absence of severe renal dysfunction, led us to
withhold plasmapheresis from the standard treatment ap-
proach. In a few anti-GBM disease patients having DAH
and normal renal function, good outcome was seen without
adding plasmapheresis to immunosuppression [44]. How-
ever, we could not find a similar case among AAV patients
or double positive patients reported to date. The unfavorable
outcome in children with double positivity and DAH, having
either low or high percentage of glomeruli with crescents
[6,14,18], strongly remind of the serious nature of the dis-
ease for which we do not still have robust indicator to assist
with optimal personalized therapy.
The outcome of reported pediatric cases is not differ-
ent from that in adults: two patients died at presentation
from massive pulmonary hemorrhage [14,18]; two pa-
tients, both dialysis dependent at presentation, remained
in end-stage renal disease (ESRD) [6]; one patient, whose
treatment was delayed 5 months after clinical onset, im-
proved renal function [16]; three patients, includingours, had normal renal function several weeks to 10
months after onset of disease [15,17]. Our patient and a
12-year old girl reported by Paueksakon et al. [15] had
normal renal function at onset with cellular crescents in
only 16% or 13% of glomeruli, respectively. These two
patients may resemble to a small subgroup of younger
adult patients with anti-GBM disease presenting with
milder kidney involvement and an excellent prognosis
despite severe pulmonary hemorrhage [44]. The third
patient, 4-year-old girl, who is the youngest patient, had
advanced disease, as shown by 62% of glomeruli with
crescents and 33% globally sclerosed, responded well to
treatment [17], similarly to very rare adult patients
[7,10,40]. On the other hand, a 17-year old girl with only
20% of crescents on biopsy was dialysis dependent at
presentation and remained in ESRD despite plasmapher-
esis and aggressive immunosuppression. No other details
are given except that she had significant glomerular
sclerosis [6]. One patient had relapse with pulmonary
hemorrhage six months after onset [6].Conclusion
The pulmonary renal syndrome is very rare in children
but represents a serious medical emergency with signifi-
cant morbidity and mortality. An early diagnosis is cru-
cial and laboratory investigation should be directed
toward testing for presence of different antibodies. The
coexistence of anti-GBM antibodies and ANCAs is ex-
ceptionally rare in children. Rapid institution of plasma-
pheresis and aggressive immunosuppressive therapy can
induce remission and preserve renal function in dual
positive patients with PRS. Prolonged therapy, long-term
follow-up and close monitoring are necessary as relapses
may occur. Renal prognosis depends on the extent of
kidney injury at diagnosis and appropriate treatment.Consent
Written informed consent was obtained from the child’s
father for publication of case report and any accompany-
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